AXLRx Travere intelligence — Rare Disease in United States: 3 reports covering Rare Disease in United States.
From zero disease-specific drugs to five in three years: how endothelin, complement and APRIL inhibitors are redrawing the IgAN market.
How US payers gate the five FDA-approved IgAN therapies — biopsy, proteinuria and RAS-blockade step-through, the Filspari REMS, Part D routing and the ICER 2026 assessment.
US IgA nephropathy epidemiology, the biopsy-and-proteinuria diagnostic gate, and the shift from RAS-blockade supportive care to five disease-modifying therapies.